Xintela AB
SSTO:XINT0.18
SEK
+0.01
(+4.12%)
ISIN
SE0007756903
Return %
Stock
S&P 500
1Y
-57.83
14.20
3Y
-31.29
81.12
5Y
-85.59
68.34
Capital Structure
SEK
•
in mil. unless spec.Working Capital
SEK
•
in mil. unless spec.Growth Rates
SEK
•
in mil. unless spec.Quarterly Revenue
SEK
•
in mil. unless spec.Quarterly Earnings Per Share
SEK
•
in mil. unless spec.Quarterly Dividends Per Share
SEK
•
in mil. unless spec.Company Description
- CEO
- Evy Lundgren-Åkerlund
- Full Time Employees
- 11
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Medicon Village Lund SN Sweden 223 81
- IPO Date
- Feb 22, 2016
- Website
- xintela.se
- Similar Companies
- Business
- Xintela AB (publ) is a biopharmaceutical firm engaged in the advanced fields of regenerative medicine and targeted oncology, concentrating on significant medical needs such as cartilage repair and aggressive tumor treatments. The company's innovative work is founded on its patented integrin α10β1 marker technology, which precisely identifies and isolates specific stem cells for therapeutic applications and targets particular cancer cells. Its flagship human stem cell product, XSTEM, is undergoing clinical evaluation for the management of knee osteoarthritis, where recent 24-month findings have demonstrated sustained safety, reduced discomfort, enhanced joint functionality, and improved cartilage and bone structure, indicating a disease-modifying capability. XSTEM is also in clinical trials for chronic, slow-healing leg ulcers, with the final patient recently treated to assess both safety and wound repair. Furthermore, Xintela is progressing XSTEM through preclinical stages for Acute Respiratory Distress Syndrome. For animal health, EQSTEM, a stem cell product targeting equine joint ailments, has been developed and is now globally licensed to EQGen Biomedical. Through its fully owned subsidiary, Targinta AB, the company is also pioneering first-in-class therapeutic antibodies, TARG9 and TARG10, that target integrin α10β1 for severe cancers, including triple-negative breast cancer, glioblastoma, and aggressive sarcoma, with a recent partnership established with Memorial Sloan Kettering Cancer Center for sarcoma antibody development. Xintela AB (publ) was established in 2009 and operates from Lund, Sweden.